tipifarnib has been researched along with pha 793887 in 4 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (pha 793887) | Trials (pha 793887) | Recent Studies (post-2010) (pha 793887) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 14 | 0 | 12 |
| Protein | Taxonomy | tipifarnib (IC50) | pha 793887 (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.138 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.06 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.062 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.06 | |
| Cyclin-A2 | Homo sapiens (human) | 0.008 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.062 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.008 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.008 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.079 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.01 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.138 | |
| Cyclin-H | Homo sapiens (human) | 0.01 | |
| Cyclin-A1 | Homo sapiens (human) | 0.008 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.005 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.005 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
4 other study(ies) available for tipifarnib and pha 793887
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |